Rosuvastatin Calcium Tablet, Film Coated
Product Images NDC 68071-3722

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rosuvastatin Calcium (NDC 68071-3722). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3722 9)

This is a description of a medication called Rosuvastatin 10mg, distributed by NuCare Pharmaceuticals, Inc. It comes in a pack of 90 film-coated tablets. Each tablet contains Rosuvastatin and Calcium USP equivalent to 10mg of Rosuvastatin. The LOT number is 00000 with NDC number 68071-3722-09. The manufacturer's NDC is 65862-294-90 and the expiration date is 00-00. There is information regarding contacting a doctor for medical advice about potential side effects and reporting such side effects to the FDA. The medication needs to be kept out of reach of children and stored at a controlled temperature of 68-77°F.*

FDA Label Image

Figure 1. Time To First Occurrence Of Major Cardiovascular Events In Jupiter (Rosuvastatin Fig1)

This text appears to be providing statistical evidence regarding a clinical trial. It includes hazard ratios (HR) and confidence intervals (CI) for different treatment groups, as well as the number at risk in each group over multiple years. The statistics suggest a significant difference between the treatment group (Rosuvastatin) and the placebo group (RSV) in terms of the outcome being measured.*

FDA Label Image

Figure 2. Major Cv Events By Treatment Group In Jupiter (Rosuvastatin Fig2)

This text appears to be a statistical analysis of clinical trial results comparing the effects of Roswa20mg and Placebo20mg on various cardiovascular endpoints. The data includes the number of events for each endpoint, hazard ratios with confidence intervals, and corresponding p-values for statistical significance. The primary endpoint (MCE) and other outcomes such as cardiovascular death, stroke, and MI are compared between the two treatment groups. The results suggest that Roswa20mg may be associated with a lower risk of adverse cardiovascular events compared to Placebo20mg.*

FDA Label Image

Figure 3. (Rosuvastatin Fig3)

This text provides information on the percent change from baseline in LDL-C levels for different doses of rosuvastatin, atorvastatin, simvastatin, and pravastatin. The doses mentioned for each statin are 10, 20, and 40 mg except for atorvastatin, which also includes a dose of 80 mg. This data can be used to compare and evaluate the efficacy of these statins in lowering LDL cholesterol levels.*

FDA Label Image

Chemical Structure (Rosuvastatin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.